Form 8-K - Current report:
SEC Accession No. 0001628280-22-013656
Filing Date
2022-05-10
Accepted
2022-05-10 17:11:28
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20220510.htm   iXBRL 8-K 36036
2 EX-99.1 a2022q1-ex991er.htm EX-99.1 204695
6 GRAPHIC cumberlandpharmaimageaa06.jpg GRAPHIC 37721
  Complete submission text file 0001628280-22-013656.txt   451003

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20220510.xsd EX-101.SCH 2011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20220510_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20220510_pre.xml EX-101.PRE 12609
8 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20220510_htm.xml XML 10578
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 22910958
SIC: 2834 Pharmaceutical Preparations